

FGD3 siRNA (m): sc-41716

BACKGROUND

FGD1 gene mutations result in faciogenital dysplasia (FGDY, Aarskog-Scott syndrome), an X-linked developmental disorder that adversely affects the formation of multiple skeletal structures. FGD1 maps to human chromosome Xp11.22 and shares a high degree of sequence identity with the FGD2 (6p21.2) and the FGD3 (9q22.31) proteins. FGD1 encodes a guanine nucleotide exchange factor that specifically activates the Rho GTPase Cdc42. FGD2 is present in several diverse tissues during embryogenesis, suggesting a role in embryonic development. FGD3 stimulates fibroblasts to form filopodia, which are Actin microspikes formed upon the stimulation of Cdc42. All FGD family members contain equivalent signaling domains and a conserved structural organization, which strongly suggests that these signaling domains form a canonical core structure for members of the FGD family of RhoGEF proteins. These proteins control essential signals required during embryonic development.

REFERENCES

1. Pasteris, N.G., et al. 1994. Isolation and characterization of the faciogenital dysplasia (Aarskog-Scott syndrome) gene: a putative Rho/Rac guanine nucleotide exchange factor. *Cell* 79: 669-678.
2. Olson, M.F., et al. 1996. Faciogenital dysplasia protein (FGD1) and Vav, two related proteins required for normal embryonic development, are upstream regulators of Rho GTPases. *Curr. Biol.* 6: 1628-1633.
3. Zheng, Y., et al. 1996. The faciogenital dysplasia gene product FGD1 functions as a Cdc42Hs-specific guanine-nucleotide exchange factor. *J. Biol. Chem.* 271: 33169-33172.
4. Pasteris, N.G., et al. 1997. Genomic organization of the faciogenital dysplasia (FGD1; Aarskog-Scott syndrome) gene. *Genomics* 43: 390-394.
5. Whitehead, I.P., et al. 1998. Cdc42 and FGD1 cause distinct signaling and transforming activities. *Mol. Cell. Biol.* 18: 4689-4697.
6. Pasteris, N.G. and Gorski, J.L. 1999. Isolation, characterization and mapping of the mouse and human FGD2 genes, faciogenital dysplasia (FGD1; Aarskog-Scott syndrome) gene homologues. *Genomics* 60: 57-66.
7. Pasteris, N.G., et al. 2000. Isolation, characterization, and mapping of the mouse FGD3 gene, a new faciogenital dysplasia (FGD1; Aarskog-Scott syndrome) gene homologue. *Gene* 242: 237-247.

CHROMOSOMAL LOCATION

Genetic locus: Fgd3 (mouse) mapping to 13 A5.

PRODUCT

FGD3 siRNA (m) is a pool of 3 target-specific 19-25 nt siRNAs designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 μ M solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see FGD3 shRNA Plasmid (m): sc-41716-SH and FGD3 shRNA (m) Lentiviral Particles: sc-41716-V as alternate gene silencing products.

For independent verification of FGD3 (m) gene silencing results, we also provide the individual siRNA duplex components. Each is available as 3.3 nmol of lyophilized siRNA. These include: sc-41716A, sc-41716B and sc-41716C.

STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNases and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 μ l of the RNase-free water provided. Resuspension of the siRNA duplex in 330 μ l of RNase-free water makes a 10 μ M solution in a 10 μ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

APPLICATIONS

FGD3 siRNA (m) is recommended for the inhibition of FGD3 expression in mouse cells.

SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 μ M in 66 μ l. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

GENE EXPRESSION MONITORING

FGD3 (A-3): sc-390256 is recommended as a control antibody for monitoring of FGD3 gene expression knockdown by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000) or immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500).

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-IgG κ BP-HRP: sc-516102 or m-IgG κ BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz Marker™ Molecular Weight Standards: sc-2035, UltraCruz® Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use m-IgG κ BP-FITC: sc-516140 or m-IgG κ BP-PE: sc-516141 (dilution range: 1:50-1:200) with UltraCruz® Mounting Medium: sc-24941 or UltraCruz® Hard-set Mounting Medium: sc-359850.

RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor FGD3 gene expression knockdown using RT-PCR Primer: FGD3 (m)-PR: sc-41716-PR (20 μ l). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.